Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution

Join us live in Atlanta or online for an expert-led satellite symposium focused on optimizing management of hemophilia A. Experts will answer audience questions and discuss the latest evidence on emerging therapeutic strategies. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Friday Satellite Symposium on Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution, preceding the 63rd ASH Annual Meeting and Exposition.


  • Introduction
  • Improving Clinical Outcomes With Factor Replacement Therapy
    An overview of factor replacement therapy including PK-driven therapy and a look at emerging agents in factor replacement
  • Optimizing Nonfactor Therapy for Hemophilia A
    Strategies for optimizing approved nonfactor therapies and an overview of new therapies currently in clinical trials
  • Mitigating Complications and Overcoming Barriers in Patients Receiving Factor Replacement Therapy
    Guidance on managing complications from factor therapy and addressing comorbidities in an aging patient population
  • Question and Answer Session
  • Key Takeaways



Date / Time
Event Details


Miguel Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Guy A. Young, MD

Professor of Pediatrics
, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with hemophilia A.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with hemophilia A.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement individualized hemophilia A prophylaxis strategies that optimize adherence, clinical outcomes, and utilization of resources
  • Identify patients who are likely to benefit from nonfactor replacement therapy
  • Mitigate complications and barriers to adherence in patients receiving factor replacement therapy
  • Apply recent safety and efficacy data for both factor replacement and nonfactor prophylaxis in hemophilia A to clinical practice
  • Manage comorbidities in patients receiving prophylaxis for hemophilia A
  • Evaluate available data for novel agents and treatment strategies, and determine patients with hemophilia A who may be eligible for enrollment on a clinical trial


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.